It's going to depend on the details of the patient, but potentially very significant in my view. I would guess that MRD with good prognosis wouldn't be enrolled in this trial to begin with.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.